13
Table 6. Common Adverse Drug Reactions and Monitoring
Recommendations
a
Drug Adverse Reactions Monitoring
Rifabutin/Rifampicin
(rifampin)
Hepatotoxicity Liver function test
Cytopenias Complete blood count
Hypersensitivity Clinical monitoring
Orange discoloration of
secretions
Amikacin, streptomycin,
tobramycin
Vestibular toxicity Clinical monitoring
Ototoxicity Audiograms
Nephrotoxicity BUN, creatinine
Electrolyte disturbances Calcium, magnesium,
potassium
Amikacin liposome
inhalation suspension
Dysphonia Clinical monitoring
Vestibular toxicity Clinical monitoring
Ototoxicity Audiograms
Nephrotoxicity BUN, creatinine
Cough Clinical monitoring
Dyspnea Clinical monitoring
Cefoxitin Cytopenias Complete blood count
Hypersensitivity Clinical monitoring
Imipenem Rashes Clinical monitoring
Cytopenias Complete blood count
Nephrotoxicity BUN/Creatinine
Tigecycline Nausea/vomiting Clinical monitoring
Hepatitis/pancreatitis Liver function tests,
amylase/lipase
a
e expert panel recommends that patients have a complete blood count, liver function tests, and
metabolic panel every 1–3 months in patients on oral therapy and weekly when on intravenous
therapy.
Monitoring frequency should be individualized based on treatment regimen, age, comorbidities,
concurrent drugs, overlapping drug toxicities, and resources.
(cont'd)
